Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Transcrocetinate sodium (Primary)
  • Indications Hypoxia
  • Focus Therapeutic Use
  • Acronyms Altitude
  • Sponsors Diffusion Pharmaceuticals

    • Most Recent Events

    • 23 Jun 2022 Positive results published in the Diffusion Pharmaceuticals Media Release.
    • 12 May 2022 According to a Diffusion Pharmaceuticals media release, data from this study will be presented by the clinical investigators at the Undersea and Hyperbaric Medical Societys Annual Scientific Meeting in Reno, Nevada being held from May 22-26, 2022.
    • 12 May 2022 According to a Diffusion Pharmaceuticals media release, last participant completed dosing in April 2022 and topline data are expected in June 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top